Am Regent Drug Patent Portfolio

Am Regent owns 5 orange book drugs protected by 15 US patents with Dexferrum having the least patent protection, holding only 1 patent. And Injectafer with maximum patent protection, holding 11 patents. Given below is the list of Am Regent's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11786548 Trace element compositions, methods of making and use 01 Jul, 2041
Active
US11975022 Trace element compositions, methods of making and use 01 Jul, 2041
Active
US11998565 Trace element compositions, methods of making and use 01 Jul, 2041
Active
US7754702 Methods and compositions for administration of iron 15 Feb, 2028
Active
US11364260 Methods and compositions for administration of iron 08 Jan, 2027
Active
US11433091 Methods and compositions for administration of iron 08 Jan, 2027
Active
US11478502 Methods and compositions for administration of iron 08 Jan, 2027
Active
US8895612 Methods and compositions for administration of iron 08 Jan, 2027
Active
US7612109 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes 05 Feb, 2025
Active
US10519252 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023 Expired
US11123321 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023 Expired
US11291645 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023 Expired
US11590097 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023 Expired
US9376505 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023 Expired
US5624668 Iron dextran formulations 29 Sep, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Am Regent.

Activity Date Patent Number
Patent litigations
Mail Patent eGrant Notification 07 May, 2024 US11975022
Patent Issue Date Used in PTA Calculation 07 May, 2024 US11975022
Email Notification 07 May, 2024 US11975022
Recordation of Patent Grant Mailed 07 May, 2024 US11975022
Patent eGrant Notification 07 May, 2024 US11975022
Recordation of Patent eGrant 07 May, 2024 US11975022
Email Notification 18 Apr, 2024 US11975022
Issue Notification Mailed 17 Apr, 2024 US11975022
Dispatch to FDC 02 Apr, 2024 US11975022
Application Is Considered Ready for Issue 02 Apr, 2024 US11975022
Issue Fee Payment Received 28 Mar, 2024 US11975022
Issue Fee Payment Verified 28 Mar, 2024 US11975022
Response to Reasons for Allowance 28 Mar, 2024 US11975022
Email Notification 22 Mar, 2024 US11975022
Mailing Corrected Notice of Allowability 22 Mar, 2024 US11975022


Am Regent's Drug Patent Litigations

Am Regent's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 24, 2015, against patent number US8895612. The petitioner Pharmacosmos A/S, challenged the validity of this patent, with Luitpold Pharmaceuticals, Inc. as the respondent. Click below to track the latest information on how companies are challenging Am Regent's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7754702 June, 2015 Final Written Decision
(04 Jan, 2017)
Luitpold Pharmaceuticals, Inc. Pharmacosmos A/S
US8895612 June, 2015 Terminated-Denied
(08 Jan, 2016)
Luitpold Pharmaceuticals, Inc. Pharmacosmos A/S


Am Regent Drug Patents' Oppositions Filed in EPO

Am Regent drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2013, by Kernebeck Patentanwalts Gmbh. This opposition was filed on patent number EP10194332A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP07716309A Apr, 2017 STADA Arzneimittel AG Granted and Under Opposition
EP07716309A Apr, 2017 Generics [U.K.] Limited Granted and Under Opposition
EP07716309A Apr, 2017 Taylor Wessing LLP Granted and Under Opposition
EP07716309A Apr, 2017 HGF Limited Granted and Under Opposition
EP07716309A Apr, 2017 TEVA PHARMACEUTICAL INDUSTRIES, LTD. Granted and Under Opposition
EP07716309A Apr, 2017 Pharmacosmos Holding A/S Granted and Under Opposition
EP07716309A Apr, 2017 Hoffmann Eitle Granted and Under Opposition
EP10194332A Feb, 2013 Kernebeck Patentanwalts GmbH Opposition rejected


Am Regent's Family Patents

Am Regent drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 28.2% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Am Regent Drug List

Given below is the complete list of Am Regent's drugs and the patents protecting them.


1. Dexferrum

Dexferrum is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5624668 Iron dextran formulations 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dexferrum's drug page


2. Injectafer

Injectafer is protected by 11 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7754702 Methods and compositions for administration of iron 15 Feb, 2028
(3 years from now)
Active
US11364260 Methods and compositions for administration of iron 08 Jan, 2027
(2 years from now)
Active
US11433091 Methods and compositions for administration of iron 08 Jan, 2027
(2 years from now)
Active
US11478502 Methods and compositions for administration of iron 08 Jan, 2027
(2 years from now)
Active
US8895612 Methods and compositions for administration of iron 08 Jan, 2027
(2 years from now)
Active
US7612109 Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes 05 Feb, 2025
(3 months from now)
Active
US10519252 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023
(11 months ago)
Expired
US11123321 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023
(11 months ago)
Expired
US11291645 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023
(11 months ago)
Expired
US11590097 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023
(11 months ago)
Expired
US9376505 Aqueous iron carbohydrate complexes, their production and medicaments containing them 20 Oct, 2023
(11 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Injectafer's drug page


3. Multrys

Multrys is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11786548 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active
US11975022 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active
US11998565 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Multrys's drug page


4. Selenious Acid

Selenious Acid is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11998565 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Selenious Acid's drug page


5. Tralement

Tralement is protected by 3 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11786548 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active
US11975022 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active
US11998565 Trace element compositions, methods of making and use 01 Jul, 2041
(16 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tralement's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List